| [1] |
Liu BB, Wang WH. Survivin and pancreatic cancer[J]. World J Clin Oncol,2011,2(3):164-168.
|
| [2] |
Kelly RJ, Lopez Chavez A, Citrin D, et al. Impacting tumor cell-fate by targeting the inhibitor of apoptosis protein survivin [J]. Molecular Cancer,2011,10(1):35.
|
| [3] |
Pennati M, Folini M, Zaffaroni N. Targeting survivin in cancer therapy: fulfilled promises and open questions [J].Carcinogenesis,2007,28(6):1133-1139.
|
| [4] |
Atlasi Y, Mowla SJ, Ziaee SA. Differential expression of survivin and its splice variants, survivin-DeltaEx 3 and survivin-2B, in bladder cancer [J]. Cancer Detect Prev,2009,32(4):308-313.
|
| [5] |
Athanassiadou AM, Patsouris E, Tsipis A, et al. The significance of survivin and Nectin-4 expression in the prognosis of breast carcinoma [J]. Folia Histochem Cytobio,2011,49(1):26-33.
|
| [6] |
Ruchaud S, Carmena M, Earnshaw WC. The chromosomal passenger complex: one for all and all for one [J]. Cell,2007,131(2):230-231.
|
| [7] |
Lladser A, Sanhueza C, Kiessling R, et al. Is survivin the potential achilles’ heel of cancer? [J]. Adv Cancer Res,2011,111(4):1-37.
|
| [8] |
Marusawa H, Matsuzawa S, Welsh K, et al. HBXIP functions as a cofactor of survivin in apoptosis suppression [J].EMBO J,2003,22(11):2729-2740.
|
| [9] |
Dohi T, Okada K, Xia F, et al. An IAP-IAP complex inhibits apoptosis [J]. J Biol Chem,2004,279(33):34 087-34 090.
|
| [10] |
Suzuki A, Ito T, Kawano H, et al. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death [J]. Oncogene,2000,19(10):1346-1353.
|
| [11] |
Altieri DC. Survivin, cancer networks and pathway-directed drug discovery [J]. Nat Rev Cancer,2008,8(1):61-70.
|
| [12] |
Lechler P, Renkawitz T, Campean V, et al. The antiapoptotic gene survivin is highly expressed in human chondrosarcoma and promotes drug resistance in chondrosarcoma cells in vitro [J]. BMC Cancer,2011,11(1):120.
|
| [13] |
Pavlidou A, Dalamaga M, Kroupis C, et al. Survivin isoforms and clinicopathological characteristics in colorectal adenocarcinomas using real-time qPCR [J]. World J Gastroenterol,2011,17(12):1614-1621.
|
| [14] |
惠燕, 黄利鸣, 叶红. Survivin 在人宫颈癌前病变和宫颈浸润癌组织中的定量分析及其临床价值的评估[J]. 肿瘤防治研究,2008,35(1):39-42.
|
| [15] |
Sohn WJ, Lee JW, Park DG. Change in expression of survivin caused by using oxaliplatin in HCT116 Colon Cancer Cells[J].J Korean Soc Coloproctol,2010,26(4):246-253.
|
| [16] |
Adamkov M, Halasova E, Kajo K, et al. Survivin: a promising biomarker in breast carcinoma [J]. Neoplasma, 2010,57(6):572-577.
|
| [17] |
Jha K, Shukla M, Pandey M. Survivin expression and targeting in breast cancer[J].Surg Oncol,2012,21(2):125-131.
|
| [18] |
Zohny SF, El-Shinawi M. Significance of survivin and Bcl-2 homologous antagonist/killer mRNA in detection of bone metastasis in patients with breast cancer[J]. Med Oncol,2011,28(S1):S108-S114.
|
| [19] |
Rexhepaj E, Jirstrom K, O’Connor DP, et al. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer[J].BMC Cancer,2010,10(5):639.
|
| [20] |
伦增军,黄勇,王静,等.乳腺癌组织中Survivin 和增殖细胞核抗原的表达及其临床意义[J/CD].中华乳腺病杂志:电子版,2009,3(3):301-308.
|
| [21] |
Petrarca CR, Brunetto AT, Duval V, et al. Survivin as a predictive biomarker of complete pathologic response to neoadjuvant chemotherapy in patients with stage Ⅱand stage Ⅲbreast cancer[J]. Clin Breast Cancer,2011,11(2):129-134.
|
| [22] |
Paik S,Shak S,Tang G,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer[J].N Engl J Med,2004,351(27):2817-2826.
|
| [23] |
Lu J, Tan M, Huang WC, et al. Mitotic deregulation by survivin in ErbB2-overexpressing breast cancer cells contributes to taxol resistance[J]. Clin Cancer Res,2009,15(4):1326-1334.
|
| [24] |
Papanikolaou V, Iliopoulos D, Dimou I, et al. Survivin regulation by HER2 through NF-κB and c-myc in irradiated breast cancer cells[J]. J Cell Mol Med,2011,15(7):1542-1550.
|
| [25] |
Moriai R, Tsuji N, Moriai M, et al. Survivin plays as a resistant factor against tamoxifen-induced apoptosis in human breast cancer cells[J]. Breast Cancer Res Treat,2009,117(2):261-271.
|
| [26] |
Nakahara T, Kita A, Yamanaka K, et al. Broad spectrum and potent antitumor activities of YM155, a novel small-molecule survivin suppressant, in a wide variety of human cancer cell lines and xenograft models[J]. Cancer Sci,2011,102(3):614-621.
|
| [27] |
Trabulo S, Cardoso AM, Santos-Ferreira T, et al. Survivin silencing as a promising strategy to enhance the sensitivity of cancer cells to chemotherapeutic agents[J].Mol Pharm,2012,21(2):125-131.
|
| [28] |
Carrasco RA,Stamm NB,Marcusson E,et al. Antisense inhibition of survivin expression as a cancer therapeutic[J]. Mol Cancer Ther,2011,10(2):221-232.
|